Bitopertin Phase 2/3 clinical trial data readouts - transfusion independence rates and hemoglobin response
FDA regulatory interactions and potential breakthrough therapy designation decisions
Cash runway updates and financing events (equity raises, partnerships, debt facilities)
Competitive clinical data from Celgene/BMS (luspatercept), Acceleron, or emerging MDS/myelofibrosis therapies
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. Patient enrollment may see modest impacts during severe recessions, but hematologic diseases require treatment regardless of economic conditions. The company's cash position buffers against short-term economic volatility.
Rising rates negatively impact valuation multiples for pre-revenue biotechs as future cash flows are discounted more heavily. Higher rates increase opportunity cost of capital, making speculative biotech investments less attractive versus fixed income. However, Disc's strong cash position ($235M+ implied by current ratio) minimizes near-term financing risk. Rate environment primarily affects stock valuation rather than operational execution.
Binary clinical trial risk - Phase 2/3 failure would eliminate primary value driver and require strategic pivot or wind-down
Regulatory approval uncertainty - FDA may require additional trials, safety data, or impose restrictive labeling limiting commercial potential
Reimbursement pressure - payers increasingly scrutinize specialty drug pricing, particularly for incremental efficacy versus existing therapies
growth - Pure clinical-stage speculation attracting biotech-focused hedge funds, venture investors, and retail momentum traders. No dividend, no earnings, valuation based entirely on probability-adjusted NPV of pipeline. Recent 20% one-year return despite -27% three-month drawdown reflects high volatility around binary events. Institutional ownership likely concentrated among healthcare specialists willing to underwrite clinical risk.
Trend
-21.0% vs SMA 50 · +21.6% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $6.1M $6.0M–$6.1M | — | -$6.00 | — | ±3% | High11 |
FY2026(current) | $3.2M $1.9M–$6.4M | ▼ -47.9% | -$6.94 | — | ±12% | High8 |
FY2027 | $32.2M $2.8M–$124.8M | ▲ +920.5% | -$7.42 | — | ±20% | High9 |
INSTITUTIONAL OWNERSHIP
IRON News
About
disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
IRON◀ | $66.86 | +0.00% | $2.6B | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.54% | — | 50.3 | +398824.8% | -4085.6% | 1500 |